Imatinib, which was the first ABL TKI introduced, induces highly hematologic and cytogenetic responses in patients newly diagnosed with CML in the chronic phase (CP) [3, 4]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.